

AWARD NUMBER: CDMRPL-16-0-DM160477

TITLE: Genomics of Early Lung Cancer Among Military Personnel (GELCAMP)

PRINCIPAL INVESTIGATOR: Robert Browning, MD FACP, FCCP

**CONTRACTING ORGANIZATION: Walter Reed National Military Medical Center
Bethesda, MD 20889**

REPORT DATE: April 2018

TYPE OF REPORT: Annual

**PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012**

**DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited**

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE

Form Approved
OMB No. 0704-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. **PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.**

1. REPORT DATE April 2018			2. REPORT TYPE Annual		3. DATES COVERED 1 Apr 2017 - 31 Mar 2018	
4. TITLE AND SUBTITLE Genomics of Early Lung Cancer Among Military Personnel (GELCAMP)					5a. CONTRACT NUMBER	
					5b. GRANT NUMBER CDMRPL-16-0-DM160477	
					5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S) Robert Browning, MD FACP, FCCP Email: robert.f.browning2.mil@mail.mil					5d. PROJECT NUMBER	
					5e. TASK NUMBER	
					5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Walter Reed National Military Medical Center Bethesda, MD 20889					8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012					10. SPONSOR/MONITOR'S ACRONYM(S)	
					11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited						
13. SUPPLEMENTARY NOTES						
14. ABSTRACT Currently several biomarkers are being validated on the DECAMP specimen, but none of these use the whole genome sequencing (WGS) technology. WGS offers a novel view of mutational changes in early lung cancer. We are testing for genomic biomarkers for the detection of early lung cancer using whole genome sequencing of DNA specimens from blood, endobronchial brushings and lung tumor specimens (for those with lung cancer). While genomic testing of lung cancer has been performed in other studies, testing other sites within the lung as well as peripheral blood for these biomarkers has not been attempted. The DEAMP cohort is unique for several reasons. The DECAMP cohort is the only cohort that specifically enrolls military personnel and offers the potential to identify mutations that might be linked to military specific exposures. It is also one of the most comprehensive and detailed cohorts associated with bronchoscopic brushings and tissue matched with CT imaging, clinical history in a longitudinal cohort.						
15. SUBJECT TERMS- Breast cancer, HSP90, small molecule inhibitors, lapatinib, oncogenic signaling						
16. SECURITY CLASSIFICATION OF:				17. LIMITATION OF ABSTRACT	18. NUMBER OF PAGES	19a. NAME OF RESPONSIBLE PERSON USAMRMC
a. REPORT U	b. ABSTRACT U	c. THIS PAGE U	19b. TELEPHONE NUMBER (include area code)			
				UU	8	

Table of Contents

	<u>Page</u>
1. Introduction.....	1
2. Keywords.....	1
3. Accomplishments.....	1
4. Impact.....	2
5. Changes/Problems.....	3
6. Products.....	4
7. Participants & Other Collaborating Organizations.....	4
8. Special Reporting Requirements.....	4
9. Appendix.....	5

- **INTRODUCTION:**

Currently several biomarkers are being validated on the DECAMP specimen, but none of these use the whole genome sequencing (WGS) technology. WGS offers a novel view of mutational changes in early lung cancer. We are testing for genomic biomarkers for the detection of early lung cancer using whole genome sequencing of DNA specimens from blood, endobronchial brushings and lung tumor specimens (for those with lung cancer). While genomic testing of lung cancer has been performed in other studies, testing other sites within the lung as well as peripheral blood for these biomarkers has not been attempted. The DEAMP cohort is unique for several reasons. The DECAMP cohort is the only cohort that specifically enrolls military personnel and offers the potential to identify mutations that might be linked to military specific exposures. It is also one of the most comprehensive and detailed cohorts associated with bronchoscopic brushings and tissue matched with CT imaging, clinical history in a longitudinal cohort.

- **KEYWORDS:**

Cancer
Lung
Biomarkers
Genomic
Genome
Tumor
DNA
Whole Genome Sequencing
WGS

- **ACCOMPLISHMENTS:**

- **What were the major goals of the project?**
 - Aim 1: Evaluate DNA copy number alterations and somatic mutations in the airway and tumor as well as germline polymorphisms that can distinguish benign vs. malignant nodules.
 - Aim 2: Characterize DNA copy number alterations and somatic mutations in the airway and tumor that associate with prognosis among those with lung cancer.
- **What was accomplished under these goals?**
 - During the past year the focus has been on administrative and regulatory tasks and preparing for specimen identification and shipping. The team has successfully obligated funds to HJF from USUHS in order to ensure the aims will be met in the given period of performance. HJF has entered into agreements with American College of Radiology and Brown University, held status meetings and assisted with regulatory requirements at WRNMMC, USU and HRPO. American College of Radiology colleagues are actively engaged on protocol efforts and administrative tasks for operationalizing study.

During the first quarter the protocol was developed and finalized and submitted to IRB at Walter Reed National Military Medical Center Bethesda (WRNMMC), reviewed and deemed exempt according to IAW 32 CFR 219.101 (b)(x). In addition the prime award from USUHS was in process. The USUHS prime award to HJF was issued during the second quarter in September 2017. The research team received letter from USUHS stating Acknowledgement of and Concurrence with the WRNMMC Exemption Determination for the Human Subjects Research Protocol #WRNMMC0-EDO-2017-0033, USU IRB#1 (FWA 00001628; DoD Assurance P60001) Protocol APG-70-8919. Therefore, the regulatory documents were submitted to HRPO for review on October 13, 2017. During the third quarter the research team received feedback from HRPO and determination that an amendment was needed due to their assessment of the protocol as non-exempt given the DECAMP protocol activity. The team quickly submitted an amendment to the WRNMMC DRP office. On April 4 2018 WRNMMC IRB provided a response with multiple stipulations which have been addressed and a response submitted.

- **What opportunities for training and professional development has the project provided?**
 - Nothing to Report.
- **How were the results disseminated to communities of interest?**
 - Nothing to Report.
- **What do you plan to do during the next reporting period to accomplish the goals?**
 - Obtain approval from WRNMMC IRB and submit amendment to protocol to USUHS and HRPO
 - Finalize iMedidata Rave access
 - Modify existing USUHS array processing SOP for GELCAMP protocol
 - Finalize existing DECAMP shipping SOP for GELCAMP requirements
 - Modify and finalize data tracking / sharing mechanism between WRNMMC and USUHS
 - Modify and maintain electronic mail distribution lists and postal directories for correspondence and communication between the coordinating center and subcontractors and service providers
 - Establish leadership teams and operational teams and schedule routine teleconferences to discuss study progress and timelines.
- **IMPACT:**
 - **What was the impact on the development of the principal discipline(s) of the project?**
 - Nothing to Report.
 - **What was the impact on other disciplines?**

- Nothing to Report.
- **What was the impact on technology transfer?**
 - Nothing to Report.
- **What was the impact on society beyond science and technology?**
 - Nothing to Report.

This project will leverage biospecimens and patient outcomes from the DECAMP trial which specifically enrolled military beneficiaries and then perform WGS at the DOD's USUHS Genomics center to find DNA biomarkers which can identify patients who have or will develop lung cancer prior to presentation with concerning clinical or radiographic findings. Biomarkers that can identify individuals with preclinical lung cancer or those at highest risk for developing lung cancer with sufficient sensitivity and specificity could be used to identify individuals who might benefit from increased lung cancer surveillance ultimately leading to earlier lung cancer diagnosis and improved lung cancer outcomes. Additionally, these biomarkers could also be used to identify the subset of individuals most likely to benefit from lung cancer chemoprophylaxis and thereby increase the efficiency of clinical trials seeking to evaluate novel agents for lung cancer chemoprevention as well as potentially *serve* as intermediate endpoints of therapeutic efficacy in those trials.

In addition, the GELCAMP WGS dataset will serve as a valuable resource for future lung cancer research in several major respects. The GELCAMP benign nodule cohort will provide the first observation of naturally occurring somatic mutation in the lung that does not progress to malignancy. Lung tumor genome analysis is complicated by the high environmentally-caused DNA damage (e.g. smoking) in which it is difficult to separate causative DNA alterations from incidental alterations. In particular, this challenge is the greatest in noncoding genomic regions, which have not yet been studied in detail due to a lack of WGS lung cancer cohorts. The GELCAMP benign nodule cohort will provide this mutational background source that can serve as a powerful control for this separation of causative versus incidental DNA alterations in future studies. Second, the combination of the GELCAMP benign and malignant cohorts will enable new genomic predictors to be constructed that will assign malignancy risk scores to future patient's nodule specimens, based on their genomic alteration profile.

- **CHANGES/PROBLEMS:**
 - **Changes in approach and reasons for change**
 - Nothing to Report.
 - **Actual or anticipated problems or delays and actions or plans to resolve them**
 - There has been 6 months of protocol submission challenges resulting in delays to start. Amended protocols have been submitted to WRNMMC and are pending administrative review.
 - **Changes that had a significant impact on expenditures**
 - Delays in protocol approval have delayed collaborators contributions.
 - **Significant changes in use or care of human subjects, vertebrate animals, biohazards, and/or select agents**
 - Nothing to Report.

- **PRODUCTS:** Nothing to Report.

- **PARTICIPANTS & OTHER COLLABORATING ORGANIZATIONS**
 - **What individuals have worked on the project?** Individuals supporting the project for the past year in excess of 160 hours are:
 - Dr. Robert Browning, PI
 - Maggie Nellissery, Coordinator

 - **Has there been a change in the active other support of the PD/PI(s) or senior/key personnel since the last reporting period?**
 - Nothing to Report.

 - **What other organizations were involved as partners?**
 - Uniform Services University, Bethesda MD
 - Bethesda MD
 - Facilities: The American Genome Center
 - Collaboration: Dr. Clifton Dalgard
 - Brown University, Providence, RI
 - Collaboration: Dr. Fenghai Duan (no contributions thus far due to protocol delay)
 - American College of Radiology, Philadelphia, PA
 - Provide analyst and coordinator at WRNMMC via a vendor contract

- **SPECIAL REPORTING REQUIREMENTS**
 - COLLABORATIVE AWARDS: Nothing to Report

- **APPENDICES:**
 - Quad Chart

Genomics of Early Lung Cancer Among Military Personnel (GELCAMP)

Funding Opportunity: DHA-16-CR11-PMRA

PI: Robert F. Browning Jr., M.D., FCCP Org: Walter Reed National Military Medical Center Award Amount: \$954,144




Study/Product Aim(s)

- Primary aim: identify airway genomic alterations in military personnel with early lung cancer that may be used as a biomarker for early diagnosis or screening.
- Secondary aim: identify genomic alterations in the airway or tumor that are prognostic in terms of predicting tumor aggressiveness among those with early stage lung cancer.

Approach

Lung cancer is a leading cause of death worldwide, and improvements in morbidity and mortality hinge on continued investigation into the biology of cancer. Whole genome sequencing can uncover cancer-associated mutations that can meaningfully impact clinical care and decision-making. In this study, blood, bronchial epithelial cells and tumor tissue (as applicable) will be sequenced from 50 cases with confirmed cancer and 50 non-cancer controls. The resulting profiles will be analyzed for genetic markers that that may enable earlier diagnosis, guide therapy decisions and improve patient outcomes.

GELCAMP Whole Genome Study



This study will utilize whole-genome sequencing of blood, bronchial epithelial cells and tumor tissue to identify biomarkers that may lead to earlier diagnosis and improved clinical outcomes in lung cancer.

This project leverages the biorepository created by DECAMP-1 to further investigate gene signatures associated with early lung cancer.

Samples from ~100 participants will be coordinated with up to two years of clinical follow-up data to correlate genetic mutations with outcomes.

Timeline and Cost

	CY17	CY18	CY19
Develop protocol and obtain HRPO, IRB approval	█		
Identify participants		█	
Data collection - Clinical		█	
Data collection - Biospecimens		█	
Data Processing – Biospecimen Arrays		█	
Data Analysis – Clinical & Arrays		█	█
Report Results / Publication			█

Estimated Budget: \$954,144

Goals/Milestones

CY17 Goals

- Develop protocol and obtain approval from HRPO, IRB
- Set up data management infrastructure to collect clinical data
- Initiate clinical data collection
- Initiate selection of biospecimens

CY18 Goals

- Complete biospecimen selection and transfer to USU for WGS sequencing

CY19 Goals

- Complete assay analysis
- Perform statistical analysis
- Prepare manuscript(s) for publication
- Publish study results

Budget Expenditure: \$14,228

Projected Expenditure: \$954,144

Updated: 13 APR 2018